Park National (AMEX:PRK) reported quarterly earnings of $2.47 per share. This is a 49.7 percent increase over earnings of $1.65 per share from the same period last year.
Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1
Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing small molecule treatments for degenerative genetic disorders, today announced new preclinical data from its novel DM1
